{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:31:32Z","timestamp":1791563492554,"version":"4.3.4"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small\/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma\/LPD (PCMZL\/LPD). The latter is still classified as primary cutaneous marginal zone lymphoma (PCMZL) in the 5th edition of the World Health Organization classification. A survey was previously carried out among 30 cutaneous lymphoma centres on the effects of this new terminology on clinical management. The results revealed considerable heterogeneity and emphasized the need to develop uniform recommendations for management and treatment of these disorders. Our objective was to develop consensus recommendations for staging, treatment and follow-up in PCSM-TCLPD, acral CD8+ TCLPD and PCMZL\/LPD. Two surveys with questions regarding staging, treatment and follow-up of cutaneous LPDs were distributed among 30 cutaneous lymphoma expert centres collaborating within the EORTC-CLTG, USCLC and ISCL. Consensus recommendations were formulated based on these surveys, an extensive literature search, two rounds of feedback and a final consensus meeting. Important changes compared with current practice and literature are as follows. (i) Staging examinations, other than thorough clinical examination of skin and peripheral lymph nodes, are not required in typical cases of PCSM-TCLPD and acral CD8+ TCLPD. (ii) Low-dose radiotherapy (4\u20138\u2005Gy) can be used rather than dose \u2265 20\u2005Gy for PCSM-TCLPD and acral CD8+ TCLPD, and 4\u2005Gy can be used for PCMZL\/LPD. The dose can be escalated to 20\u201324\u2005Gy in the case of local failure. (iii) Intralesional corticosteroids are also recommended as initial treatment in all three LPDs. (iv) A limited follow-up period (2\u2005years) is acceptable in PCSM-TCLPD and acral CD8+ TCLPD LPD. These EORTC\/USCLC\/ISCL consensus recommendations reflect the state-of-the-art management and treatment as agreed upon by major cutaneous lymphoma centres. They may contribute to uniform staging, treatment and follow-up policy in patients with cutaneous LPDs.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf312","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:34:55Z","timestamp":1754393695000},"page":"1090-1100","source":"Crossref","is-referenced-by-count":16,"title":["European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-7616","authenticated-orcid":false,"given":"Rein","family":"Willemze","sequence":"first","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Busschots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cerroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fina","family":"Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Diercks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A","family":"Gru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Koldijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00e1","family":"Marschalk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Mitteldorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Molg\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Muniesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J","family":"Neelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pulitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-5809","authenticated-orcid":false,"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Quint","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia J","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u00a0M\u00a0R","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-4613","authenticated-orcid":false,"given":"Maarten","family":"Vermeer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Leiden University Medical Center , Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6293-2554","authenticated-orcid":false,"given":"Marion","family":"Wobser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2025111813165842700_ljaf312-B1","volume-title":"World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2017","edition":"4th edn"},{"key":"2025111813165842700_ljaf312-B2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"2025111813165842700_ljaf312-B3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2025111813165842700_ljaf312-B4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"2025111813165842700_ljaf312-B5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/cup.14609","article-title":"Cutaneous lymphoproliferative disorders: back to the future","volume":"51","author":"Willemze","year":"2024","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/PAS.0b013e318230df87","article-title":"Expression of programmed death-1 in primary cutaneous CD4-positive small\/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma","volume":"36","author":"Cetin\u00f6zman","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"2025111813165842700_ljaf312-B7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/PAS.0000000000001470","article-title":"Primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorders: a clinical, pathologic and molecular study of 60 cases presenting with a single lesion: a multicenter study of the French Cutaneous Lymphoma Study Group","volume":"44","author":"Beltzung","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"2025111813165842700_ljaf312-B8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/his.14834","article-title":"Cyclin D1 expression, cell proliferation, and clonal persistence characterize primary cutaneous CD4+ small or medium T-cell lymphoproliferative disorder","volume":"82","author":"Oschlies","year":"2023","journal-title":"Histopathology"},{"key":"2025111813165842700_ljaf312-B9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/PAS.0b013e31818e52fe","article-title":"Primary cutaneous CD4+ small\/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers","volume":"33","author":"Rodr\u00edguez Pinilla","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"2025111813165842700_ljaf312-B10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/cup.12234","article-title":"Evaluation of follicular T-helper cells in primary cutaneous CD4+ small\/medium pleomorphic T-cell lymphoma and dermatitis","volume":"40","author":"Ally","year":"2013","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/ajcp\/aqaa116","article-title":"How I diagnose primary cutaneous marginal zone lymphoma","volume":"154","author":"Gibson","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"2025111813165842700_ljaf312-B12","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1097\/DAD.0000000000002003","article-title":"Primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorder or primary cutaneous marginal zone B-cell lymphoma? Two distinct entities with overlapping histopathological features","volume":"43","author":"Bakr","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"2025111813165842700_ljaf312-B13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/PAS.0000000000001984","article-title":"Overlapping features of primary cutaneous marginal zone lymphoproliferative disorder and primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorder: a diagnostic challenge examined by genomic analysis","volume":"47","author":"Obiorah","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"2025111813165842700_ljaf312-B14","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/cup.14697","article-title":"Primary cutaneous lymphoproliferations in the gray zone between marginal zone lymphoma and CD4+ small\/medium T-cell lymphoproliferative disease","volume":"51","author":"P\u00e1los","year":"2024","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/DAD.0b013e31819f19bb","article-title":"Primary cutaneous CD4+ small-\/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases","volume":"31","author":"Beltraminelli","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"2025111813165842700_ljaf312-B16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1159\/000511473","article-title":"The clinical spectrum of primary cutaneous CD4+ small\/medium-sized pleomorphic T-cell lymphoproliferative disorder: an updated systematic literature review and case series","volume":"237","author":"Surmanowicz","year":"2021","journal-title":"Dermatology"},{"key":"2025111813165842700_ljaf312-B17","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/cup.12806","article-title":"Clinicopathological and molecular study of primary cutaneous CD4+ small\/medium-sized pleomorphic T-cell lymphoma","volume":"43","author":"Alberti-Violetti","year":"2016","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B18","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1200\/JCO.2008.16.1307","article-title":"Primary cutaneous small\/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome","volume":"26","author":"Garcia-Herrera","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025111813165842700_ljaf312-B19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/10428194.2014.938331","article-title":"CD4+ primary cutaneous small\/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature","volume":"56","author":"James","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2025111813165842700_ljaf312-B20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bjd.21791","article-title":"Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study","volume":"187","author":"Wang","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025111813165842700_ljaf312-B21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/ijd.13340","article-title":"Long-term follow-up and management of small and medium-sized CD4+ T-cell lymphoma and CD8+ lymphoid proliferations of acral sites: a multicenter experience","volume":"55","author":"Virmani","year":"2016","journal-title":"Int J Dermatol"},{"issue":"Suppl. 4","key":"2025111813165842700_ljaf312-B22","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"2025111813165842700_ljaf312-B23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025111813165842700_ljaf312-B24","doi-asserted-by":"crossref","first-page":"109430","DOI":"10.1016\/j.radonc.2022.11.019","article-title":"Excellent treatment outcomes from low dose radiation therapy for primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorder","volume":"178","author":"Ward","year":"2023","journal-title":"Radiother Oncol"},{"key":"2025111813165842700_ljaf312-B25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/ijd.17352","article-title":"Radiotherapy in the treatment of primary cutaneous CD4+ small\/medium T-cell lymphoproliferative disorder","volume":"64","author":"Wu","year":"2025","journal-title":"Int J Dermatol"},{"key":"2025111813165842700_ljaf312-B26","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/pde.13728","article-title":"Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoproliferative disorder in a pediatric patient successfully treated with low-dose radiation","volume":"36","author":"Kim","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"2025111813165842700_ljaf312-B27","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1097\/PAS.0b013e318068b527","article-title":"Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma?","volume":"31","author":"Petrella","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"2025111813165842700_ljaf312-B28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0560.2009.01278.x","article-title":"Indolent CD8+ lymphoid proliferation of the ear: a phenotypic variant of the small-medium pleomorphic cutaneous T-cell lymphoma?","volume":"37","author":"Beltraminelli","year":"2010","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1600-0560.2010.01647.x","article-title":"Indolent CD8+ lymphoid proliferation of the ear: report of two cases and review of the literature","volume":"38","author":"Swick","year":"2011","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B30","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/cup.12213","article-title":"Extrafacial indolent CD8-positive cutaneous lymphoid proliferation with unusual symmetrical presentation involving both feet","volume":"40","author":"Wobser","year":"2013","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/cup.12045","article-title":"Indolent CD8+ lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features","volume":"40","author":"Greenblatt","year":"2013","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/DAD.0b013e3182a74c7a","article-title":"Multicenter case series of indolent small\/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face","volume":"36","author":"Li","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"2025111813165842700_ljaf312-B33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/cup.12633","article-title":"Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient","volume":"43","author":"Kluk","year":"2016","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjd.20973","article-title":"Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop","volume":"186","author":"Kempf","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025111813165842700_ljaf312-B35","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/bjd.13628","article-title":"CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas","volume":"172","author":"Wobser","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025111813165842700_ljaf312-B36","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/cup.13020","article-title":"Primary cutaneous acral CD8 positive T-cell lymphoma with extra-cutaneous involvement: a long-standing case with an unexpected progression","volume":"44","author":"Alberti-Violetti","year":"2017","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B37","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2002-07-1960","article-title":"Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients","volume":"102","author":"Bekkenk","year":"2003","journal-title":"Blood"},{"key":"2025111813165842700_ljaf312-B38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/biomedicines11020634","article-title":"Primary cutaneous multifocal indolent CD8+ T-cell lymphoma: a novel primary cutaneous CD8+ T-cell lymphoma","volume":"11","author":"Petrogiannis-Haliotis","year":"2023","journal-title":"Biomedicines"},{"key":"2025111813165842700_ljaf312-B39","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2340\/00015555-2002","article-title":"Disseminated primary cutaneous CD8+ small\/medium-sized pleomorphic T-cell lymphoma responding to hydroxychloroquine","volume":"95","author":"Amann","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2025111813165842700_ljaf312-B40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cup.12509","article-title":"Rethinking primary cutaneous marginal zone lymphoma: shifting the focus to the cause of the infiltrate","volume":"42","author":"Guitart","year":"2015","journal-title":"J Cutan Pathol"},{"key":"2025111813165842700_ljaf312-B41","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch Dermatol"},{"key":"2025111813165842700_ljaf312-B42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2008.04.012","article-title":"Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome in primary cutaneous marginal zone lymphoma","volume":"59","author":"Gerami","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2025111813165842700_ljaf312-B43","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00000478-199608000-00010","article-title":"Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients","volume":"20","author":"Bailey","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"2025111813165842700_ljaf312-B44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2559.1993.tb00469.x","article-title":"Cutaneous immunocytomas: a clinicopathologic study of 26 cases","volume":"23","author":"Rijlaarsdam","year":"1993","journal-title":"Histopathology"},{"key":"2025111813165842700_ljaf312-B45","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/00000478-199711000-00005","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma","volume":"21","author":"Cerroni","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"2025111813165842700_ljaf312-B46","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jid.2018.02.015","article-title":"Panel sequencing shows recurrent genetic FAS alterations in primary cutaneous marginal zone lymphoma","volume":"138","author":"Maurus","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2025111813165842700_ljaf312-B47","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/modpathol.2013.106","article-title":"Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression","volume":"26","author":"Brenner","year":"2013","journal-title":"Mod Pathol"},{"key":"2025111813165842700_ljaf312-B48","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/PAS.0000000000001363","article-title":"Class-switched primary cutaneous marginal zone lymphomas are frequently IgG4-positive and have features distinct from IgM-positive cases","volume":"43","author":"Carlsen","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"2025111813165842700_ljaf312-B49","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.15183","article-title":"Myeloid differentiation primary response 88 mutations in a distinct type of cutaneous marginal-zone lymphoma with a nonclass-switched immunoglobulin M immunophenotype","volume":"177","author":"Wobser","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025111813165842700_ljaf312-B50","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"2025111813165842700_ljaf312-B51","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J Clin Oncol"},{"key":"2025111813165842700_ljaf312-B52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients","volume":"69","author":"Servitje","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025111813165842700_ljaf312-B53","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jaad.2019.01.037","article-title":"Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin","volume":"81","author":"Kheterpal","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025111813165842700_ljaf312-B54","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","article-title":"Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets","volume":"34","author":"Edinger","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"2025111813165842700_ljaf312-B55","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/his.15377","article-title":"Recurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patients","volume":"86","author":"Beltzung","year":"2025","journal-title":"Histopathology"},{"key":"2025111813165842700_ljaf312-B56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"2025111813165842700_ljaf312-B57","author":"National Comprehensive Cancer Network. NCCN guidelines. Primary cutaneous lymphoma"},{"key":"2025111813165842700_ljaf312-B58","first-page":"1379","article-title":"Borrelia burgdorferi in primary cutaneous lymphomas: a systematic review and meta-analysis","volume":"18","author":"Travaglino","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025111813165842700_ljaf312-B59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2141.2008.07159.x","article-title":"Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma","volume":"142","author":"Senff","year":"2008","journal-title":"Br J Haematol"},{"key":"2025111813165842700_ljaf312-B60","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamadermatol.2013.9223","article-title":"High incidence of gastrointestinal tract disorders and autoimmunity in primary cutaneous marginal zone B-cell lymphomas","volume":"150","author":"Guitart","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2025111813165842700_ljaf312-B61","first-page":"537","article-title":"S2k guideline \u2013 cutaneous lymphomas (ICD10 C82-C86): update 2021","volume":"20","author":"Dippel","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025111813165842700_ljaf312-B62","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.det.2022.07.014","article-title":"A practical review of the presentation, diagnosis, and management of cutaneous B-cell lymphomas","volume":"41","author":"Goyal","year":"2023","journal-title":"Dermatol Clin"},{"key":"2025111813165842700_ljaf312-B63","doi-asserted-by":"crossref","first-page":"e3215","DOI":"10.1002\/hon.3215","article-title":"Identifying and addressing unmet clinical needs in primary cutaneous B-cell lymphoma: a consensus-based paper from an ad-hoc international panel","volume":"42","author":"Quaglino","year":"2024","journal-title":"Hematol Oncol"},{"key":"2025111813165842700_ljaf312-B64","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2133.2010.09798.x","article-title":"Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma","volume":"163","author":"Perry","year":"2010","journal-title":"Br J Dermatol"},{"key":"2025111813165842700_ljaf312-B65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"International Lymphoma Radiation Oncology Group. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025111813165842700_ljaf312-B66","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/jvc2.403","article-title":"Ultra-low radiation therapy for primary cutaneous indolent B-cell lymphomas","volume":"3","author":"Kazera","year":"2024","journal-title":"JEADV Clin Pract"},{"key":"2025111813165842700_ljaf312-B67","doi-asserted-by":"crossref","first-page":"115064","DOI":"10.1016\/j.ejca.2024.115064","article-title":"Radiotherapy in cutaneous lymphomas: recommendations from the EORTC cutaneous lymphoma tumour group","volume":"212","author":"Elsayad","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025111813165842700_ljaf312-B68","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.3390\/cancers14194787","article-title":"Treatment of indolent cutaneous B-cell lymphoma with intralesional or intravenous rituximab","volume":"14","author":"Menzer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025111813165842700_ljaf312-B69","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jaad.2020.07.028","article-title":"Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry","volume":"83","author":"Muniesa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025111813165842700_ljaf312-B70","first-page":"174","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study","volume":"167","author":"Pe\u00f1ate","year":"2012","journal-title":"The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf312\/63969658\/ljaf312.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1090\/63969658\/ljaf312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1090\/63969658\/ljaf312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:17:14Z","timestamp":1763489834000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/6\/1090\/8223474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,6]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf312","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,6]]}}}